Top Markets
#1 MowCat MowCat +369.83%
#2 龙虾 (Lobster) 龙虾 (Lobster) +66.68%
#3 SODAX SODAX +47.27%
#4 Cortex Cortex +34.03%
#5 OpenEden OpenEden +24.18%
#6 DexNet DexNet +23.19%
#7 Akedo Akedo +16.57%
#8 wojak wojak +16.21%
#9 Magma Finance Magma Finance +15.83%
#10 MANTRA MANTRA +15.75%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Hualan Biological Bacterin Inc. Hualan Biological Bacterin Inc.

Hualan Biological Bacterin Inc.

301207
Rank in Stocks #7577
Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on... Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of immunizations, including various influenza virus vaccines (such as split, quadrivalent, and H1N1 strains), recombinant hepatitis B vaccines, and meningococcal polysaccharide vaccines (including ACYW135 and Group A & C types). They also develop genetically engineered vaccines for human use. Established in 2005, Hualan Biological Bacterin Inc. is headquartered in Xinxiang, China, and previously operated as a subsidiary of Hualan Biological Engineering Inc.
Share Price
$2.58
Market Cap
$1.54B
Change (1 day)
-2.46%
Change (1 year)
2.58%
Country
CN
Trade Hualan Biological Bacterin Inc. (301207)

Category

Healthcare
Revenue for Hualan Biological Bacterin Inc. (301207)
Revenue in Aug 2026 TTM: 0
According to Hualan Biological Bacterin Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hualan Biological Bacterin Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH